Biogen
BIIB
$216.65
-0.85%
Biogen is an established biopharmaceutical company focused on developing and commercializing treatments for neurodegenerative and rare diseases, with its multiple sclerosis franchise contributing 40% of total revenue in 2025. The company holds a strong market position in neurology, leveraging collaborations with Roche (CD20 therapies) and partnerships with Ionis and Eisai to expand its portfolio. Currently, the investor narrative centers on Biogen's strategic pivot toward immunology and rare diseases, highlighted by the acquisitions of Apellis and RayThera, while navigating the decline of its legacy MS products and mixed clinical trial results for Alzheimer's candidates. Recent news indicates a positive market reaction to Q2 earnings and improved revenue guidance, but concerns persist around pipeline setbacks and the integration of new acquisitions.…
BIIB
Biogen
$216.65
Related headlines
Investment Opinion: Should I buy BIIB Today?
We rate BIIB as a Buy, driven by the strategic pivot to immunology and rare diseases, a forward PE of 13.2x that undervalues expected earnings growth, and a strong balance sheet. The analyst consensus is a Buy with an average target of $236.22, implying 8.1% upside from the current price of $218.50.
Sign up to view all
BIIB 12-Month Price Forecast
The AI assessment is bullish, with medium confidence, as the valuation and analyst sentiment support upside, but the sluggish revenue growth and pipeline risks temper conviction. The stock's strong momentum and strategic pivot to high-growth areas are positive, but the negative PEG ratio and clinical setbacks warrant caution. An upgrade to high confidence would require evidence of accelerating revenue growth and successful pipeline progress, while a downgrade would occur if the stock breaks below $200 or if earnings estimates are cut significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Biogen's 12-month outlook, with a consensus price target around $236.22 and implied upside of +9.0% versus the current price.
Average Target
$236.22
0 analysts
Implied Upside
+9.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$165 - $300
Analyst target range
The target price range spans from $165 to $300, with the high target reflecting expectations of successful pipeline launches and margin expansion, while the low target prices in potential clinical failures or competitive pressures. Recent institutional ratings show a mix of actions, including upgrades from Truist Securities (Hold to Buy) and Needham (Hold to Buy), while Morgan Stanley maintained Equal Weight, indicating a cautiously optimistic sentiment. The wide spread between the low and high targets suggests that analysts have divergent views on the company's ability to execute its growth strategy, particularly in the competitive Alzheimer's and immunology markets.
Bulls vs Bears: BIIB Investment Factors
Biogen presents a compelling turnaround story, with strong momentum, a strategic pivot to high-growth areas, and a forward valuation that implies substantial earnings growth. However, the sluggish revenue growth, pipeline setbacks, and integration risks temper the optimism. Currently, the bull case has stronger evidence, supported by analyst upgrades and a 64.7% 1-year stock surge, but the key tension lies in whether the company can convert its pipeline and acquisitions into sustained revenue and earnings growth. If clinical failures or integration issues emerge, the stock could quickly lose its premium.
Bullish
- Strong momentum with 64.7% 1-year gain: BIIB has surged 64.72% over the past year, far outpacing the S&P 500's 18.56% gain. This reflects growing investor confidence in the company's strategic pivot and recent execution, as the stock trades near its 52-week high of $222.85.
- Attractive forward valuation at 13.2x PE: With a forward PE of 13.21x versus a trailing PE of 19.89x, the market expects significant earnings growth. This is supported by analyst EPS estimates averaging $20.55 for the next fiscal year, implying a 35%+ earnings jump from current levels.
- Q2 beat and raised guidance: Biogen's Q2 2026 earnings beat expectations and management improved full-year revenue guidance, signaling that the strategic pivot toward immunology and rare diseases is gaining traction. This positive news drove the stock to top the market on July 29.
- Diversification via acquisitions: The acquisitions of Apellis and RayThera add high-growth drugs and an early-stage immunology pipeline, reducing reliance on the declining MS franchise. Apellis brings two fast-growing drugs, while RayThera targets a $112B immunology market.
Bearish
- Alzheimer's trial miss creates uncertainty: In May 2026, Biogen's Alzheimer's drug diranersen missed its primary clinical endpoint, causing a sharp selloff. Although secondary data showed promise, the miss raises doubts about the pipeline's near-term value and could lead to further setbacks.
- Revenue growth remains sluggish: Q1 2026 revenue grew only 1.93% YoY, and the multi-quarter trend shows a plateau between $2.28B and $2.65B. The decline in MS products is only partially offset by newer drugs, limiting top-line expansion.
- Negative PEG ratio signals earnings risk: The PEG ratio of -0.95 indicates expected negative earnings growth in the near term, likely due to acquisition-related costs and heavy R&D spending. This could pressure profitability and justify the lower forward PE.
- Integration risks from recent acquisitions: Biogen paid up to $1 billion for RayThera, a company that hasn't disclosed its pipeline, and completed the Apellis acquisition, which pressures the balance sheet. Integration challenges could distract management and delay synergies.
BIIB Technical Analysis
Biogen's stock is in a strong uptrend, with a 1-year price change of +64.72%, significantly outperforming the S&P 500's +18.56% over the same period. The current price of $218.50 sits near the top of its 52-week range, at approximately 98% of the high of $222.85, indicating robust momentum and investor confidence. This positioning near highs suggests the market is rewarding the company's strategic initiatives, though it also raises the risk of a short-term pullback if sentiment shifts.
Beta
0.16
0.16x market volatility
Max Drawdown
-14.3%
Largest decline past year
52-Week Range
$134-$223
Price range past year
Annual Return
+63.9%
Cumulative gain past year
| Period | BIIB Return | S&P 500 |
|---|---|---|
| 1m | +6.8% | +2.7% |
| 3m | +14.7% | +1.0% |
| 6m | +14.1% | +12.0% |
| 1y | +63.9% | +18.9% |
| ytd | +21.8% | +12.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BIIB Fundamental Analysis
Biogen's revenue growth has been modest but positive, with Q1 2026 revenue of $2.48 billion, up 1.93% year-over-year, following a slight decline in Q4 2025. The multi-quarter trend shows revenue fluctuating between $2.28 billion and $2.65 billion, with Q2 2025 being the peak, indicating a plateau rather than a clear growth trajectory. The company's newer franchises, such as Spinraza and Skyclarys, are helping offset the decline in its MS products, but the overall growth rate remains subdued, reflecting the challenges of a maturing portfolio.
Quarterly Revenue
$2.5B
2026-03
Revenue YoY Growth
+1.9%
YoY Comparison
Gross Margin
73.3%
Latest Quarter
Free Cash Flow
$2.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BIIB Overvalued?
Given Biogen's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 19.89x, while the forward PE is 13.21x, implying that the market expects significant earnings growth in the next year. This gap suggests that investors are pricing in a recovery in profitability, likely driven by cost synergies from recent acquisitions and pipeline progress. The PEG ratio is negative (-0.95), which is unusual and indicates that earnings growth is expected to be negative in the near term, potentially due to acquisition-related costs or R&D investments.
PE
19.9x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~38x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.38, which is manageable, but the company's net margin of 13.2% is thin for a biotech, and Q4 2025 posted a net loss of -$48.4 million. The negative PEG ratio (-0.95) suggests near-term earnings headwinds from acquisition costs and R&D investments. Revenue concentration is a concern, with the MS franchise still contributing 40% of total revenue, and the CD20 collaboration with Roche adds another 19%, making Biogen vulnerable to competitive pressures in these mature markets.
FAQ
The key risks are: (1) Pipeline failures, such as the Alzheimer's drug diranersen missing its primary endpoint, which could lead to significant selloffs; (2) Integration risks from the Apellis and RayThera acquisitions, which could distract management and delay synergies; (3) Competitive pressure in the MS market, where the franchise is declining and faces new entrants; (4) Macro risks, though the low beta of 0.16 reduces market correlation. The most severe risk is a major clinical failure, which could push the stock to the 52-week low of $131.52, a -39.8% downside.
The 12-month forecast is bullish, with a base case target of $236.22 (analyst average), a bull case of $300, and a bear case of $165. The base case has a 50% probability, assuming revenue growth of 2-3% and EPS of $20.55. The bull case (30% probability) requires successful pipeline launches and accelerated growth, while the bear case (20% probability) involves clinical failures and integration issues. The most likely scenario is the base case, with the stock trading around $236, but the wide range reflects high uncertainty.
BIIB is undervalued relative to its forward earnings, with a forward PE of 13.2x versus the trailing PE of 19.9x, indicating the market expects significant earnings growth. The stock trades at 2.63x sales and 9.6x EV/EBITDA, which is reasonable for a biotech with a 70.5% gross margin. Compared to the sector average, BIIB's forward PE is a discount, suggesting the market is pricing in execution risks. The negative PEG ratio (-0.95) is a red flag, but it reflects near-term earnings headwinds from acquisitions, not a long-term issue. Overall, the stock is fairly valued, with upside if the company delivers on its growth plan.
BIIB is a good buy for investors with a medium-to-long-term horizon, given the forward PE of 13.2x and analyst average target of $236.22, implying 8.1% upside. The stock has strong momentum, up 64.7% in 1 year, and the strategic pivot to immunology and rare diseases could drive growth. However, the biggest risk is pipeline failure, as seen with the Alzheimer's trial miss, which could lead to a -39.8% downside to the 52-week low of $131.52. For risk-tolerant investors, the risk/reward is attractive, but those seeking stability may want to wait for more clarity on pipeline progress.
BIIB is more suitable for long-term investment, given its strategic pivot and pipeline potential, which will take time to materialize. The stock has a low beta of 0.16, indicating lower volatility, and no dividend, so it is not for income investors. The earnings visibility is moderate, with analyst estimates for EPS of $20.55, but clinical and integration risks make short-term trading risky. A minimum holding period of 2-3 years is recommended to allow the acquisitions to contribute and pipeline to advance. Short-term traders may find opportunities around earnings and clinical data releases, but the stock's momentum could reverse quickly on bad news.